FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989006112> ?p ?o ?g. }

• W2989006112 abstract "Abstract Background Genomic alterations of receptor tyrosine kinases (RTK) or ligands are biomarkers for some targeted therapies in a fraction of cancers, with heterogeneous responses across tumor types. A general model to predict the efficacy of a targeted treatment in a given tumor type bearing a RTK genomic alteration is lacking. Through database and literature review, we investigated whether the role of a RTK in the normal lineage could predict the response to RTK inhibitors in cancers arising from the same lineage. Methods An analysis of the literature and query of public databases on RTK function in normal cell lineages and neoplastic cells was conducted, for 16 selected RTK (EGFR, HER2, KIT, FLT3, TRKA-B-C, ROS1, ALK, RET, MET, and FGFR1-2-3-4). The physiological role of RTK in the development/maintenance of cell lineages was assessed by looking at the phenotypes resulting from the alteration of the RTK in animal models and/or known human germline mutations. The activity of TKI monotherapy in genomic-driven clinical trials was analyzed through a systematic review of published phase I-II-III studies. Efficacy was defined as a median progression-free survival > 6 months and of a response rate > 30%. A matrix was built to test the association between the physiological role and clinical activity of each RTK according to lineage contexts. Results This analysis reveals a relationship between the role in lineage development and the magnitude of clinical activity of a TKI in a cancer arising from the same lineage. For missense mutations only, the clinical activity was higher when the RTK is involved in the development or maintenance of the normal cell lineage. Conversely, in cancers harboring fusion genes and proteins involving an RTK, TKI were active regardless of cell lineage. Single agent TKI activity was consistently limited in cancers bearing RTK gene amplifications. Conclusions This analysis identifies two preferred genomic biomarkers to select candidate patient for single agent TKI, 1) fusions genes involving an RTK; 2) activating missense mutations in RTK involved in normal cell lineage physiology. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure P.A. Cassier: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Research grant / Funding (institution): Blueprint; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Research grant / Funding (institution): Tayo; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Innate. I.L. Ray-Coquard: Honoraria (self), Research grant / Funding (self): Roche; Honoraria (self), Research grant / Funding (institution): Amgen; Honoraria (self), Research grant / Funding (institution): Genmab; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Pfizer. D. Perol: Honoraria (self): AstraZeneca; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): Lilly; Honoraria (self): Bristol-Myers Squibb. J-Y. Blay: Research grant / Funding (self): PharmaMar; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Novartis; Research grant / Funding (self): Eisai; Research grant / Funding (self): Lilly; Research grant / Funding (self): Merck Sharp and Dohme; Research grant / Funding (self): Bristol-Myers Squibb. All other authors have declared no conflicts of interest." @default.
• W2989006112 created "2019-11-22" @default.
• W2989006112 creator A5007748719 @default.
• W2989006112 creator A5009481448 @default.
• W2989006112 creator A5012166159 @default.
• W2989006112 creator A5019588141 @default.
• W2989006112 creator A5027371764 @default.
• W2989006112 creator A5043045128 @default.
• W2989006112 creator A5057508902 @default.
• W2989006112 creator A5073713547 @default.
• W2989006112 creator A5079058944 @default.
• W2989006112 creator A5081037927 @default.
• W2989006112 creator A5090555713 @default.
• W2989006112 date "2019-11-01" @default.
• W2989006112 modified "2023-09-27" @default.
• W2989006112 title "Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers" @default.
• W2989006112 doi "https://doi.org/10.1093/annonc/mdz413.083" @default.
• W2989006112 hasPublicationYear "2019" @default.
• W2989006112 type Work @default.
• W2989006112 sameAs 2989006112 @default.
• W2989006112 citedByCount "0" @default.
• W2989006112 crossrefType "journal-article" @default.
• W2989006112 hasAuthorship W2989006112A5007748719 @default.
• W2989006112 hasAuthorship W2989006112A5009481448 @default.
• W2989006112 hasAuthorship W2989006112A5012166159 @default.
• W2989006112 hasAuthorship W2989006112A5019588141 @default.
• W2989006112 hasAuthorship W2989006112A5027371764 @default.
• W2989006112 hasAuthorship W2989006112A5043045128 @default.
• W2989006112 hasAuthorship W2989006112A5057508902 @default.
• W2989006112 hasAuthorship W2989006112A5073713547 @default.
• W2989006112 hasAuthorship W2989006112A5079058944 @default.
• W2989006112 hasAuthorship W2989006112A5081037927 @default.
• W2989006112 hasAuthorship W2989006112A5090555713 @default.
• W2989006112 hasBestOaLocation W29890061121 @default.
• W2989006112 hasConcept C101544691 @default.
• W2989006112 hasConcept C104317684 @default.
• W2989006112 hasConcept C121608353 @default.
• W2989006112 hasConcept C126322002 @default.
• W2989006112 hasConcept C127716648 @default.
• W2989006112 hasConcept C151730666 @default.
• W2989006112 hasConcept C184235292 @default.
• W2989006112 hasConcept C2776817793 @default.
• W2989006112 hasConcept C2779343474 @default.
• W2989006112 hasConcept C502942594 @default.
• W2989006112 hasConcept C54355233 @default.
• W2989006112 hasConcept C71924100 @default.
• W2989006112 hasConcept C86803240 @default.
• W2989006112 hasConceptScore W2989006112C101544691 @default.
• W2989006112 hasConceptScore W2989006112C104317684 @default.
• W2989006112 hasConceptScore W2989006112C121608353 @default.
• W2989006112 hasConceptScore W2989006112C126322002 @default.
• W2989006112 hasConceptScore W2989006112C127716648 @default.
• W2989006112 hasConceptScore W2989006112C151730666 @default.
• W2989006112 hasConceptScore W2989006112C184235292 @default.
• W2989006112 hasConceptScore W2989006112C2776817793 @default.
• W2989006112 hasConceptScore W2989006112C2779343474 @default.
• W2989006112 hasConceptScore W2989006112C502942594 @default.
• W2989006112 hasConceptScore W2989006112C54355233 @default.
• W2989006112 hasConceptScore W2989006112C71924100 @default.
• W2989006112 hasConceptScore W2989006112C86803240 @default.
• W2989006112 hasLocation W29890061121 @default.
• W2989006112 hasOpenAccess W2989006112 @default.
• W2989006112 hasPrimaryLocation W29890061121 @default.
• W2989006112 hasRelatedWork W10207493 @default.
• W2989006112 hasRelatedWork W12342559 @default.
• W2989006112 hasRelatedWork W13135763 @default.
• W2989006112 hasRelatedWork W13281499 @default.
• W2989006112 hasRelatedWork W1495669 @default.
• W2989006112 hasRelatedWork W2036746 @default.
• W2989006112 hasRelatedWork W2526890 @default.
• W2989006112 hasRelatedWork W5533728 @default.
• W2989006112 hasRelatedWork W9608172 @default.
• W2989006112 hasRelatedWork W976714 @default.
• W2989006112 isParatext "false" @default.
• W2989006112 isRetracted "false" @default.
• W2989006112 magId "2989006112" @default.
• W2989006112 workType "article" @default.